ClinicalTrials.gg
RecruitingNCT07150975Updated Nov 25, 2025

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

A Phase 3 interventional study of GZR18 and Semaglutide(Wegovy® ) in Obesity/Overweight in Adult, sponsored by Gan & Lee Pharmaceuticals.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Planned enrollment
2nd of 15
420 · median 140
Started
2025
with 5 others
Phase 3
5 of 15
3 open now
Registered
11th of 15
by date
Lead sponsor
9 of 15
Gan & Lee Pharmaceuticals.

Among the 15 studies testing bofanglutide in Obesity, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 3, and was the 11th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.

03

Conditions studied

  • Obesity/Overweight in Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old (based on the date of signing the form), male or female.
  2. For subjects not diagnosed with type 2 diabetes at screening, the following criteria must be met:

    At screening and Visit 2 (before randomization), the subject must be either obese ( ≥ 28 kg/m²) or overweight (24 kg/m² ≤ BMI \< 28 kg/m²), and concurrently present with at least one of the following conditions:

    • Comorbidity of one or more of the following: hyperglycemia (see Appendix 1 for definition), hypertension, dyslipidemia (see Appendix 2 for definition), or fatty liver; ②Weight-bearing joint pain;

      • Weight-related obstructive sleep apnea syndrome.
  3. For subjects with type 2 diabetes at screening, the following criteria must be met simultaneously:

    Body mass index (BMI) ≥ 24 kg/m² at both screening and Visit 2 (before randomization); A confirmed diagnosis of type 2 diabetes for at least 90 days at screening, in accordance with the World Health Organization (WHO) 1999 diabetes diagnostic criteria and the 2011 supplementary diagnostic criteria (-based diagnosis is recommended); Within 90 days prior to screening: ① Management through diet and exercise alone, with no use of any antidiabetic medications; or ② Treatment of type 2 diabetes with a stable dose of metformin monotherapy, where the metformin dose is ≥ 1500 mg/day or the maximum tolerated dose (\< 1500 mg/day but ≥ 1000 mg/day); or ③ Treatment of type 2 diabetes with a stable dose of metformin (≥ 1500 mg/day or the maximum tolerated dose (\< 1500 mg/day but ≥ 1000 mg/day)) combined with a stable dose of sodium-glucose cotransporter 2 inhibitor (SGLT2i); Glycated hemoglobin (HbA1c) measured by the central laboratory at screening is 7.0-10.5% (inclusive of both endpoints); Fasting plasma glucose measured by the central laboratory at screening is \< 15 mmol/L.

  4. Prior to screening, the subject has been managed by diet and exercise alone for at least 12 weeks, and the body weight change has been \< 5% within the past 12 weeks (based on self-report).
  5. Subjects of must have no childbearing plans from the time of signing the informed consent form to 8 weeks after the last dose, and voluntarily adopt effective measures, with no plans for sperm/egg donation. Females of childbearing potential must not be breastfeeding, and the pregnancy test results must be negative at both screening and Visit 2 (before randomization).
  6. The subject must be able to understand the procedures and methods of this study, be willing and able to maintain a regular diet and exercise lifestyle during the study period, be willing and able to receive subcutaneous injection of the product, and voluntarily sign the informed consent form.

    -

Exclusion criteria

Exclusion Criteria:

  1. For subjects without type 2 diabetes at screening, the following situations are excluded:

    • Fasting plasma glucose ≥ 7.0 mmol/L or (HbA1c) ≥ 6.5% as measured by the central laboratory at screening.

      • Diagnosis of any type of diabetes (excluding gestational diabetes) prior to screening.

        • Use of glucagon-like peptide-1 receptor (GLP-1R) agonists or drugs with a GLP-1R agonist mechanism of action (e.g., GLP-1R/glucagon receptor (GCGR) agonists, glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonists, or GIPR/GLP-1R/GCGR agonists, etc.) prior to screening.
  2. For subjects with type 2 diabetes at screening, the following situations are excluded:

    • Use of glucagon-like peptide-1 receptor (GLP-1R) agonists or drugs with a GLP-1R agonist mechanism of action (e.g., GLP-1R/glucagon receptor (GCGR) agonists, glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonists, or GIPR/GLP-1R/GCGR agonists, etc.) within 180 days prior to screening; or a history of poor blood glucose control efficacy or intolerance to the above-mentioned drugs (as assessed by the investigator).

      • A history of diabetic ketoacidosis, lactic acidosis, or hyperosmolar hyperglycemic state within 180 days prior to screening.

        • Presence of severe chronic diabetic complications at screening (e.g., proliferative retinopathy or macular edema, painful diabetic neuropathy, intermittent claudication, or diabetic foot).

          • A history of or complicated urinary tract infections/genital infections within 6 months prior to screening.
  3. Subjects with known or suspected allergies to glucagon-like peptide-1 (GLP-1) receptor agonists or their .
  4. A history of substance abuse prior to screening.
  5. A history of alcohol abuse within 180 days prior to screening, defined as an average weekly alcohol intake exceeding 14 units (for males)/7 units (for females) (1 standard unit is equivalent to 360 mL of beer, 150 mL of wine with 12% alcohol content, or 45 mL of spirits with 40% alcohol content).
  6. Presence of limb deformities or disabilities that affect height measurement.
  7. Previous receipt of bariatric surgery prior to screening, or planned receipt of bariatric surgery during the study period (exceptions include acupuncture for weight loss, liposuction, or abdominal liposuction performed more than 1 year prior to screening; and removal (or expulsion) of intragastric balloons more than 1 year prior to screening).
  8. Obesity caused by secondary diseases or medications, including: elevated cortisol (e.g., Cushing's syndrome), obesity due to pituitary or hypothalamic damage, etc.
  9. A history of severe hypoglycemia or grade 3 hypoglycemia within 180 days prior to screening.
  10. A personal history or relevant family history of medullary thyroid carcinoma, multiple endocrine neoplasia (MEN) type 2A or 2B prior to screening; or a history of malignant tumors within the past 5 years (excluding cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).
  11. The investigator deems that the subject has any other factors that may affect the evaluation of efficacy or safety in this study, making them unsuitable for participation.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    GZR18 Dose Level 1

    Drug: GZR18

  • Experimental
    GZR18 Dose Level 2

    Drug: GZR18

  • Active comparator
    Semaglutide(Wegovy® )2.4 mg

    Drug: Semaglutide(Wegovy® )

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline after 52 weeks (W) of treatment.

    Time frame: From Week 0 to Week 52

Secondary outcomes

  1. Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 5% from baseline

    Time frame: From Week 0 to Week 52

  2. Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 10% from baseline

    Time frame: From Week 0 to Week 52

  3. Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 15% from baseline

    Time frame: From Week 0 to Week 52

  4. Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 20% from baseline

    Time frame: From Week 0 to Week 52

  5. Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 25% from baseline

    Time frame: From Week 0 to Week 52

  6. Efficacy Outcome Measure :Changes in body weight from baseline

    Time frame: From Week 0 to Week 52

  7. Efficacy Outcome Measure :Changes in body mass index (BMI) from baseline

    Time frame: From Week 0 to Week 52

  8. Efficacy Outcome Measure :Changes in waist circumference from baseline

    Time frame: From Week 0 to Week 52

  9. Efficacy Outcome Measure :Changes from baseline in glycated hemoglobin (HbA1c)

    Time frame: From Week 0 to Week 52

  10. Efficacy Outcome Measure :Changes from baseline in fasting plasma glucose

    Time frame: From Week 0 to Week 52

  11. Efficacy Outcome Measure :Changes from baseline in fasting insulin

    Time frame: From Week 0 to Week 52

  12. Efficacy Outcome Measure :Changes insystolic blood pressure from baseline

    Time frame: From Week 0 to Week 52

  13. Efficacy Outcome Measure :Changes in diastolic blood pressure from baseline

    Time frame: From Week 0 to Week 52

  14. Efficacy Outcome Measure :Changes from baseline in total cholesterol (TC)

    Time frame: From Week 0 to Week 52

  15. Efficacy Outcome Measure :Changes from baseline in low-density lipoprotein cholesterol (LDL-C)

    Time frame: From Week 0 to Week 52

  16. Efficacy Outcome Measure :Changes from baseline in high-density lipoprotein cholesterol (HDL-C)

    Time frame: From Week 0 to Week 52

  17. Efficacy Outcome Measure :Changes from baseline in triglycerides (TG)

    Time frame: From Week 0 to Week 52

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 21 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 2, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07150975
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Sep 23, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 25, 2025

Study contacts

Jianbo Song
Contact
jianbo.song@ganlee.com
010-56456739

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion